trending Market Intelligence /marketintelligence/en/news-insights/trending/ttM2jWNztGaxUQrccJk66A2 content esgSubNav
In This List

Medicure files abbreviated application with US FDA for cardiovascular drug

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Medicure files abbreviated application with US FDA for cardiovascular drug

Medicure Inc. filed an abbreviated new drug application to the U.S. FDA for a cardiovascular generic drug, developed as a collaboration between Medicure unit Medicure International Inc. and Apicore US LLC.

The filing was the result of a project focused on the development of an intravenous drug product for an acute cardiovascular indication.

The company and Apicore have entered into an exclusive product supply and development agreement under which Medicure holds all commercial rights.

Medicure currently owns majority interest in Apicore, with an option to acquire the remaining issued shares of Apicore until July 2017.